Gilead infectious news

The University of California's California HIV/AIDS Research Program awarded $11.8 million in three grants to investigators evaluating pre-exposure prophylaxis (PrEP) with Gilead's HIV drug Truvada emtricitabine/tenofovir. Two grants will cover studies evaluating the safety and feasibility of PrEP with Truvada along with risk-reduction counseling and screening for sexually transmitted infections in about 700 high-risk uninfected individuals in Southern California over the next four years. The studies will also evaluate adherence, risk behavior and HIV seroconversion over a 48-week period. The third grant will fund a consortium to plan and pilot strategies to offer PrEP to high-risk uninfected young men of color. ...